Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016

Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016

Abstract Background Oncotype DX® (ODX) is used to assess risk of disease recurrence in hormone receptor positive, HER2-negative breast cancer and to guide decisions regarding adjuvant chemotherapy. Little is known about how physician factors impact treatment decisions. The purpose of this study was...

Full description

Bibliographic Details
Main Authors: Thomas M. Schwedhelm, Judy R. Rees, Tracy Onega, Ronnie J. Zipkin, Andrew Schaefer, Maria O. Celaya, Erika L. Moen
Format: Article
Language:English
Published: BMC 2020-09-01
Series:BMC Cancer
Subjects:
Oncotype DX
Breast cancer
Adjuvant chemotherapy
Online Access:http://link.springer.com/article/10.1186/s12885-020-07355-6

Internet

http://link.springer.com/article/10.1186/s12885-020-07355-6

Similar Items